🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 21 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 27/01/2004 | 10,44 | 10,51 | 9,80 | 9,87 | -5,82% | 6,80% | 852.500 |
| 26/01/2004 | 10,21 | 10,52 | 10,07 | 10,48 | +0,29% | 4,41% | 604.400 |
| 23/01/2004 | 10,44 | 10,49 | 10,28 | 10,45 | +1,46% | 2,01% | 529.100 |
| 22/01/2004 | 10,28 | 10,55 | 10,14 | 10,30 | +0,29% | 3,99% | 859.300 |
| 21/01/2004 | 9,86 | 10,76 | 9,83 | 10,27 | +2,09% | 9,43% | 957.200 |
| 20/01/2004 | 10,35 | 10,36 | 9,70 | 10,06 | +0,00% | 6,38% | 1.077.800 |
| 16/01/2004 | 9,83 | 10,15 | 9,75 | 10,06 | +1,72% | 4,07% | 1.125.500 |
| 15/01/2004 | 9,49 | 10,08 | 9,38 | 9,89 | +2,17% | 7,38% | 877.500 |
| 14/01/2004 | 9,60 | 9,71 | 9,48 | 9,68 | +1,89% | 2,40% | 419.400 |
| 13/01/2004 | 9,58 | 9,60 | 9,45 | 9,50 | +0,42% | 1,57% | 1.144.800 |
| 12/01/2004 | 10,02 | 10,29 | 9,45 | 9,46 | -6,34% | 8,38% | 1.625.600 |
| 09/01/2004 | 10,11 | 10,70 | 10,01 | 10,10 | -3,63% | 6,82% | 970.500 |
| 08/01/2004 | 10,40 | 10,56 | 10,29 | 10,48 | +0,77% | 2,60% | 388.900 |
| 07/01/2004 | 10,13 | 10,43 | 9,90 | 10,40 | +3,17% | 5,23% | 739.200 |
| 06/01/2004 | 10,09 | 10,36 | 10,04 | 10,08 | -0,40% | 3,17% | 618.700 |
| 05/01/2004 | 10,55 | 10,68 | 10,10 | 10,12 | -3,62% | 5,50% | 910.300 |
| 02/01/2004 | 10,35 | 10,75 | 10,23 | 10,50 | +1,45% | 5,02% | 544.900 |
| 31/12/2003 | 10,40 | 10,45 | 10,00 | 10,35 | +0,19% | 4,33% | 1.207.900 |
| 30/12/2003 | 10,22 | 10,50 | 10,20 | 10,33 | +1,08% | 2,94% | 527.900 |
| 29/12/2003 | 9,98 | 10,42 | 9,90 | 10,22 | +2,71% | 5,21% | 842.700 |
| 26/12/2003 | 9,65 | 9,95 | 9,65 | 9,95 | +2,79% | 3,11% | 197.900 |
| 24/12/2003 | 9,66 | 9,82 | 9,45 | 9,68 | +0,41% | 3,83% | 239.000 |
| 23/12/2003 | 9,42 | 9,80 | 9,38 | 9,64 | +3,43% | 4,46% | 876.500 |
| 22/12/2003 | 9,00 | 9,34 | 8,94 | 9,32 | +2,42% | 4,44% | 551.400 |
| 19/12/2003 | 9,12 | 9,20 | 8,90 | 9,10 | -0,22% | 3,29% | 896.700 |
| 18/12/2003 | 9,01 | 9,28 | 8,94 | 9,12 | +1,22% | 3,77% | 731.700 |
| 17/12/2003 | 9,04 | 9,13 | 8,88 | 9,01 | -0,44% | 2,77% | 533.700 |
| 16/12/2003 | 8,93 | 9,09 | 8,90 | 9,05 | +1,34% | 2,13% | 496.300 |
| 15/12/2003 | 9,30 | 9,34 | 8,91 | 8,93 | -2,51% | 4,62% | 591.300 |
| 12/12/2003 | 9,22 | 9,32 | 9,00 | 9,16 | -0,54% | 3,47% | 351.800 |